Strides Pharma Science’s arm, Pii get nod for Potassium Chloride Extended-Release Tablets

02 Apr 2019 Evaluate

Strides Pharma Science’s step-down wholly owned subsidiary -- Vensun Pharmaceuticals, Inc., USA and its partner Pharmaceutics International, Inc. (Pii) have received approval for jointly developed Potassium Chloride Extended-Release Tablets USP, 10 mEq (750 mg), 15 mEq (1,125 mg), and 20 mEq (1,500 mg) product from the United States Food & Drug Administration (USFDA).

The product is an immediately dispersing extended-release oral dosage form of potassium chloride and is a generic version of Potassium Chloride Extended-Release Tablets of Merck, Inc. According to IQVIA MAT data, the US market for Potassium Chloride Extended Release Tablets with the current reference product is approximately $ 240 million. The product will be manufactured by Pii and will be marketed by Strides in the US market.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.

Strides Pharma Scien Share Price

796.20 -68.60 (-7.93%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×